Clearside Biomedical

Clearside Biomedical EBIT Growth

Delisted

The Year-over-Year EBIT Growth of Clearside Biomedical (CLSD) as of Nov 20, 2026 is -16.25 %. In the previous year, Year-over-Year EBIT Growth was 17.95 % — a change of -190.54% (lower).

EBIT Growth

-16.25 %

YoY

-190.54%

Last updated:

Year-over-Year EBIT Growth of Clearside Biomedical is 2024 -16.25 % . Year-over-Year EBIT Growth of Clearside Biomedical was 2023 17.95 % . It decreases by -190.54% lower compared to the previous year.

The Clearside Biomedical EBIT Growth history

  • 3 Years

  • 10 Years

  • 25 Years

  • Max

EBIT Growth
Date
EBIT Growth
Jan 1, 2017
-131.79 USD
Jan 1, 2018
-42.01 USD
Jan 1, 2019
63.47 USD
Jan 1, 2020
40.79 USD
Jan 1, 2021
96.54 USD
Jan 1, 2022
-4,783.87 USD
Jan 1, 2023
17.95 USD
Jan 1, 2024
-16.25 USD
The Clearside Biomedical EBIT Growth history
YEAREBIT GrowthYoY
-16.25 %-190.54%
17.95 %-100.38%
-4,783.87 %-5,055.12%
96.54 %+136.67%
40.79 %-35.73%
63.47 %-251.08%
-42.01 %-68.12%
-131.79 %+189.66%
-45.50 %-40.43%
-76.37 %—

Access this data via the Eulerpool API

100,000 free requests/mo · no credit card

Clearside Biomedical Stock analysis

What does Clearside Biomedical do? Clearside Biomedical, Inc. generates revenue through the development of drug therapies for blinding eye diseases, targeting the retina, choroid, and sclera. The company’s lead product candidate, XIPERE, is a proprietary, preservative-free suspension of the corticosteroid triamcinolone acetonide administered via suprachoroidal injection. This clinical stage biopharmaceutical firm focuses on treating conditions affecting these specific eye components to restore or preserve vision. The business model relies on advancing its proprietary therapies through clinical development rather than immediate commercial sales. By concentrating on the retina, choroid, and sclera, Clearside Biomedical, Inc. addresses critical anatomical areas involved in visual health. The company operates from its headquarters in Alpharetta, Georgia, with a dedicated team supporting its research and development efforts. Financial viability is tied to the successful progression of its drug candidates, particularly XIPERE, which utilizes a unique delivery method for triamcinolone acetonide. The firm engages in the biopharmaceutical sector by developing treatments for diseases that impact the structural and functional integrity of the eye. Its strategy centers on innovation in drug formulation and administration to treat blinding conditions effectively. Clearside Biomedical is one of the most popular companies on Eulerpool.

Frequently Asked Questions about Clearside Biomedical stock

Year-over-Year EBIT Growth of Clearside Biomedical is -16.25 % in 2024.

On Eulerpool you can find the complete historical development of Year-over-Year EBIT Growth Clearside Biomedical since 2006 – with annual values, charts, and detailed analysis.

EBIT growth measures the percentage change in operating earnings. It shows whether a company's core operations are becoming more profitable.

To evaluate Year-over-Year EBIT Growth's, it is essential to compare it with peers in the same industry and sector. On Eulerpool, you can find direct industry comparisons for Year-over-Year EBIT Growth.

Year-over-Year EBIT Growth's is a key factor for investors. Changes in this metric can signal improving or deteriorating fundamentals, directly impacting the stock price. On Eulerpool, you can track Year-over-Year EBIT Growth's Clearside Biomedical historically and in real time.

Access this data via the Eulerpool API

100,000 free requests/mo · no credit card

Growth — Clearside Biomedical

All Key Metrics — Clearside Biomedical